The orally taken, once-daily treatments are based on its proprietary dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) programmes, which are in pre-clinical studies currently.
Sareum added both programmes (SDC-1801 for autoimmune diseases and SDC-1802 for cancer) are continuing to receive interest from international pharmas.
Tim Mitchell, chief executive, said: "We are very pleased with the progress of our proprietary dual TYK2/JAK1 programmes.
“We believe these offer a novel oral immunotherapy approach to addressing unmet needs in autoimmune diseases and cancer and that their mechanism is gaining increasing interest from the pharmaceutical industry.
Sareum is looking to secure commercial licences for the late pre-clinical or early clinical stages of their development
Mitchell also remains hopeful that partner Sierra Oncology will be able to find the funds to develop cancer treatment molecule SRA737, especially after encouraging clinical results in June and good indications from pre-clinical combinations with other therapies.
Losses were £1.45mln after tax in the year to June, with cash in the bank of £0.92mln though that does not include a further £780,000 raised in July.